Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 721 to 730 of 1557 total matches.

Pegcetacoplan (Syfovre) for Geographic Atrophy in Age-Related Macular Degeneration

   
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023  (Issue 1673)
. The Medical Letter ® Vol. 65 (1673) April 3, 2023 50 Over 24 months, pegcetacoplan statistically ...
The FDA has approved the complement C3 inhibitor pegcetacoplan (Syfovre – Apellis) for treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Given as a series of monthly or every-other-month (EOM) intravitreal injections, it is the first drug to become available for use in patients with atrophic dry AMD. Subcutaneous pegcetacoplan was approved earlier as Empaveli for treatment of paroxysmal nocturnal hemoglobinuria.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):49-50   doi:10.58347/tml.2023.1673a |  Show IntroductionHide Introduction

Omalizumab (Xolair) for Food Allergy

   
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024  (Issue 1699)
. A constellation of symptoms similar to those seen in patients determined. The Medical Letter ® Vol. 66 (1699 ...
Omalizumab (Xolair – Genentech), a recombinant anti-IgE monoclonal antibody FDA-approved for treatment of allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic urticaria, has now also been approved for use in conjunction with food allergen avoidance to reduce IgE-mediated food allergic reactions caused by accidental exposure in patients ≥1 year old. Omalizumab is the first drug to be approved in the US to reduce allergic reactions to more than one food. Palforzia, an oral peanut allergen powder, was approved in 2020 to mitigate allergic reactions caused by...
Med Lett Drugs Ther. 2024 Apr 1;66(1699):54-6   doi:10.58347/tml.2024.1699b |  Show IntroductionHide Introduction

Cologuard Plus — An At-Home Stool DNA Test for Colorectal Cancer Screening

   
The Medical Letter on Drugs and Therapeutics • May 12, 2025  (Issue 1728)
be followed by a diagnostic colonoscopy. The Medical Letter ® Vol. 67 (1728) May 12, 2025 ...
The FDA has approved Cologuard Plus (Exact Sciences), a new at-home multitarget stool DNA test, for colorectal cancer (CRC) screening in average-risk adults ≥45 years old. Cologuard, the first FDA-approved multitarget stool DNA test, has been available since 2014.
Med Lett Drugs Ther. 2025 May 12;67(1728):73-5   doi:10.58347/tml.2025.1728a |  Show IntroductionHide Introduction

Oral Contraceptives

   
The Medical Letter on Drugs and Therapeutics • May 15, 2000  (Issue 1078)
Street, New Rochelle, N.Y. 10801 • A Nonprofit Publication Vol. 42 (W1078B) May 15, 2000 REPRODUCED ...
Two types of oral contraceptives are available in the USA: combination oral contraceptives that contain both an estrogen and a progestin, and progestin-only contraceptives, or "mini-pills."Used as directed, all oral contraceptives marketed in the USA are similarly effective in preventing pregnancy.
Med Lett Drugs Ther. 2000 May 15;42(1078):42-4 |  Show IntroductionHide Introduction

Yasmin -- an Oral Contraceptive With a New Progestin

   
The Medical Letter on Drugs and Therapeutics • Jun 24, 2002  (Issue 1133)
Letter, Inc. • 1000 Main Street, New Rochelle, N.Y. 10801 • A Nonprofit Publication Vol. 44 (W1133A ...
An oral contraceptive (Yasmin - Berlex) containing 3 mg of drospirenone and 30 mcg of ethinyl estradiol is being promoted as having a low incidence of adverse effects.
Med Lett Drugs Ther. 2002 Jun 24;44(1133):55-7 |  Show IntroductionHide Introduction

Cholesterol Rethink for High-Risk Patients

   
The Medical Letter on Drugs and Therapeutics • May 10, 2004  (Issue 1182)
Publication Vol. 46 (Issue 1182) May 10, 2004 EDITOR: Mark Abramowicz, M.D. DEPUTY EDITOR: Gianna Zuccotti ...
The recent "PROVE IT" trial in patients with coronary heart disease showed clinical benefits associated with reducing LDL cholesterol concentrations lower than the 100 mg/dL (2.59 mmol/L) or less that had been considered optimal.
Med Lett Drugs Ther. 2004 May 10;46(1182):37-9 |  Show IntroductionHide Introduction

Fluticasone Furoate (Arnuity Ellipta) for Asthma

   
The Medical Letter on Drugs and Therapeutics • May 25, 2015  (Issue 1469)
to fluticasone propionate in improving trough FEV1 from baseline. 77 The Medical Letter ® Vol. 57 (1469 ...
The FDA has approved Arnuity Ellipta (GSK), a single-agent inhaler containing the corticosteroid fluticasone furoate, for once-daily maintenance treatment of asthma in patients ≥12 years old. Fluticasone furoate is also available in combination with the long-acting beta2-agonist vilanterol as Breo Ellipta for treatment of asthma and COPD.
Med Lett Drugs Ther. 2015 May 25;57(1469):76-9 |  Show IntroductionHide Introduction

Phexxi - A Nonhormonal Contraceptive Gel

   
The Medical Letter on Drugs and Therapeutics • Aug 24, 2020  (Issue 1605)
of 12 single-use applicators costs $267.50. 130 The Medical Letter ® Vol. 62 (1605) August 24, 2020 ...
The FDA has approved Phexxi (Evofem), a nonhormonal prescription-only vaginal gel containing lactic acid, citric acid, and potassium bitartrate, for prevention of pregnancy. The gel is intended for on-demand contraception; it is not effective when used after intercourse. It was previously approved for use as a vaginal lubricant (Amphora), but was never marketed.
Med Lett Drugs Ther. 2020 Aug 24;62(1605):129-32 |  Show IntroductionHide Introduction

Ceftobiprole Medocaril (Zevtera) — A New Cephalosporin Antibiotic

   
The Medical Letter on Drugs and Therapeutics • Sep 15, 2025  (Issue 1737)
is a prodrug of the active moiety ceftobiprole. The Medical Letter ® Vol. 67 (1737) September 15, 2025 150 ...
Ceftobiprole medocaril sodium (Zevtera – Innoviva Specialty Therapeutics), a new IV cephalosporin antibacterial drug, has been approved by the FDA for treatment of Staphylococcus aureus bacteremia (SAB), including right-sided infective endocarditis, acute bacterial skin and skin structure infections (ABSSSIs), and community-acquired bacterial pneumonia (CABP) (see Table 1). It is the second cephalosporin with activity against methicillin-resistant S. aureus (MRSA) to be approved in the US; ceftaroline (Teflaro), which was approved for treatment of ABSSSIs and CABP in 2010, was the...
Med Lett Drugs Ther. 2025 Sep 15;67(1737):149-52   doi:10.58347/tml.2025.1737d |  Show IntroductionHide Introduction

Drugs for Sexually Transmitted Infections

   
The Medical Letter on Drugs and Therapeutics • Jun 27, 2022  (Issue 1653)
undiagnosed HIV, and data on the effectiveness of The Medical Letter ® Vol. 64 (1653) June 27, 2022 98 ...
This article includes recommendations for management of most sexually transmitted infections (STIs) other than HIV and viral hepatitis. Some of the indications and dosages recommended here have not been approved by the FDA (see Table 1).
Med Lett Drugs Ther. 2022 Jun 27;64(1653):97-104 |  Show IntroductionHide Introduction